Content for healthcare professionals only

View all Platforms Cardiology

Topics Content Type Videos Articles Journals Broadcasts Education Podcasts News Journals AER CFR ECR ICR3 JAPSC USC Faculty Events Upcoming Events Radcliffe Events All Events Resource Hubs Empagliflozin in the Treatment of Chronic Heart Failure Pulmonary Embolism Pulsed Field Ablation

Radcliffe Platforms

Radcliffe Group Cardiology Vascular CVRM Medical Education

Content for healthcare professionals only

Content Type

Events

Resource Hubs

Controversies Regarding Subclinical Leaflet Thrombosis After TAVR

Published: 25 February 2021

Views:
1800
Likes:
7

Views:
1800
Likes:
7
Share:

Now Playing
Part 3 | Session 2 of 3
CONTRA
Renate B Schnabel

Up Next
11m 57s

Part 3 | Session 3 Panel discussion & Audience Questions
Jolanta Siller-Matula, Mamas A Mamas, Poonam Velagapudi, Kimberly Atianzar, Renate B Schnabel

15m 20s

Part 1 Subclinical leaflet thrombosis after TAVR: Numbers and facts Jolanta Siller-Matula

10m 22s

Part 2 | Session 1 PRO Mamas A Mamas

10m 45s

Part 2 | Session 2 CONTRA Poonam Velagapudi

13m 38s

Part 2 | Session 3 Panel discussion & Audience Questions Jolanta Siller-Matula, Mamas A Mamas, Poonam Velagapudi, Kimberly Atianzar, Renate B Schnabel

11m 47s

Part 3 | Session 1 PRO Kimberly Atianzar

Average (ratings)

No ratings

Your rating

Overview

A substantial number of patients develop a subclinical leaflet thrombosis (SLT) after transcatheter aortic valve replacement (TAVR).

The thrombus forms on the leaflets, which can lead to valve dysfunction and possibly to early valve degeneration. Multidetector computed tomography is the most sensitive imaging technique at detecting SLT.

Patients on antiplatelet drugs are at higher risk to develop SLT as compared to those on anticoagulants. During the live debate, the experts in the field will discuss controversies concerning SLT, including the routine use of oral anticoagulants and CT exams after TAVR.

Learning Objectives

To learn about the natural history, incidence and clinical implications of SLT
To learn about the mechanisms that may lead to SLT
To understand the diagnostic criteria SLT
To discuss the prevention and treatment options for SLT

Audience

Interventional cardiologists with focus on TAVR procedures
Cardiac Imaging specialists (Echocardiography, Computer Tomography)
General cardiologists
Specialists interested in management of antithrombotic therapies after TAVR

More from this programme

Part 1

Subclinical leaflet thrombosis after TAVR: Numbers and facts

1 session
Subclinical leaflet thrombosis after TAVR: Numbers and facts	Watch now

Part 2

Debate: Patients should receive routine CT screening after TAVR to exclude subclinical valve thrombosis

3 sessions
PRO	Watch now
CONTRA	Watch now
Panel discussion & Audience Questions	Watch now

Part 3

Debate: Patients should be routinely discharged on oral anticoagulants for prevention of subclinical valve thrombosis after TAVR

3 sessions
PRO	Watch now
CONTRA	Watch now
Panel discussion & Audience Questions	Watch now

Faculty Biographies

Renate Schnabel

Renate Schnabel

Consultant in Cardiology

Renate Schnabel is a consultant in cardiology at University Heart Centre Hamburg, Germany. She graduated from medical school in Mainz, Germany in 2002. After a research fellowship at the Framingham Heart Study, Boston University, she moved to Hamburg. She works with clinical and population cohorts and leads national and EU-funded international consortia. She is PI of the German Centre for Cardiovascular Research. Her research interest is in digital cardiology, atrial fibrillation and heart failure, and omics for cardiovascular risk assessment. Very active within professional organizations, she is member on councils of the European Society of Cardiology, American Heart Association and the German Cardiac Society.

View full profile